ACALABRUTINIB

Information current as at: 1 March 2025

PBAC meeting date: November 2021
Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Calquence®
Pharmaceutical company:
AstraZeneca Pty Ltd
Condition/indication:
(therapeutic use)
  • Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
PBAC Submission type:
Change to listing (–)
Comment:
--
Related medicines:

Progress Details

Submission received for:
November 2021 PBAC meeting
Opportunity for consumer comment:
Open 28/07/2021 and close 22/09/2021 (see PBS Website)
PBAC meeting:
Held on 03/11/2021
PBAC outcome published:
Not Recommended (see PBAC Outcomes)
Lodgement of required documentation:
Not applicable
Agreement to listing arrangements:
Not applicable
Government processes:
Not applicable
Medicine listed on the PBS:
Not applicable

Case ID: a390

Page last updated: 31 October 2024

v.9.18